Prelude Capital Management’s Astrana Health ASTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,843
Closed -$225K – 1677
2026
Q2
$225K Buy
+4,843
New +$174K 0.02% 929
2025
Q4
– Sell
-12,382
Closed -$351K – 1605
2025
Q3
$351K Buy
+12,382
New +$336K 0.03% 649
2025
Q1
– Sell
-7,284
Closed -$230K – 1577
2024
Q4
$230K Buy
+7,284
New +$346K 0.01% 927
2021
Q4
– Sell
-14,873
Closed -$1.35M – 2306
2021
Q3
$1.35M Buy
+14,873
New +$1.26M 0.03% 444
2020
Q4
– Sell
-500
Closed -$9K – 2091
2020
Q3
$9K Buy
+500
New +$8.63K ﹤0.01% 1475
2019
Q1
– Sell
-419
Closed -$8K – 2260
2018
Q4
$8K Hold
419
– – ﹤0.01% 1433
2018
Q3
$9K Buy
+419
New +$8.82K ﹤0.01% 1489

Other funds holding ASTH

Prelude Capital Management's ASTH Position: Q3 2026 in Review

Prelude Capital Management sold out of Astrana Health (ASTH) in Q3 2026, closing a stake of 4,843 shares — an estimated $225K sold.

Prelude Capital Management first reported a position in ASTH in Q3 2018 and held it in 7 quarters. The position peaked at $1.35M in Q3 2021. 218 funds tracked by Wall St. Rank hold ASTH as of Q3 2026.

  • Prelude Capital Management reported no remaining Astrana Health position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 4,843 Astrana Health shares in Q3 2026, an estimated $225K.
  • Prelude Capital Management first reported a position in Astrana Health in Q3 2018 and held it in 7 quarters.
  • Prelude Capital Management's Astrana Health position peaked at $1.35M in Q3 2021.
  • 218 funds tracked by Wall St. Rank held Astrana Health as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.